expands partnership with Samsung Biologics for PMC-403
South Korea, Sep 21, 2020
/PRNewswire/ -- PharmAbcine
Inc. (KOSDAQ: 208340ks) entered into a strategic
partnership with Samsung Biologics (KRX: 207940.KS) for the development and
manufacturing of PMC-403 pipeline, the next generation therapeutic antibody
candidate to treat neovascular disorders. Samsung will provide the full scope of
its CDO services from cell line development, process development, cGMP clinical
manufacturing to IND filing support.
is a clinical-stage biotech company developing fully human therapeutic
antibodies to treat cancer and neovascular disease. Olinvacimab, the company's
lead molecule, is in phase II clinical trials for a combination therapy to
treat cancer with Merck's Keytruda.
is a novel agonistic antibody that binds to the human Tie2 receptor.
PharmAbcine is developing PMC-403 as a therapeutic drug for both non ocular and
ocular pathological vessel related diseases. The company expects PMC-403 to
enter a global ophthalmological clinical trial in 2022.
PharmAbcine signed a material cooperative research collaboration agreement with
the National Institute of Allergy and Infectious Diseases (NIAID), part of the
National Institutes of Health (NIH), in which NIAID will assess the efficacy of
PMC-403 to treat Systemic Capillary Leak Syndrome (SCLS or Clarkson
“This marks a
significant turning point for PharmAbcine because we are finally taking the
actual steps to expand the indications of our angiogenesis assets beyond
oncology,” said Dr. Jin-San Yoo, CEO of PharmAbcine. “We expect to use
PMC-403 molecules produced under this contract in not only preclinical research
collaboration with NIAID for SCLS therapeutics but
also our own R&D efforts to treat various vascular diseases.”
About PharmAbcine Inc.
is a clinical-stage biotech company focusing on the development of fully human
antibody therapeutics to treat neovascular disorders, tumors, and other
medically unmet diseases. It provides therapeutic antibodies for a wide spectrum
of indications from oncology, immuno-oncology, ophthalmology, respiratory, to
leading pipeline, olinvacimab, an anti-VEGFR2 neutralizing fully human IgG, is
currently in a phase II study for bevacizumab-nonresponding rGBM (recurrent
glioblastoma multiforme) patients in both US and Australia. In collaboration
with MERCK, olinvacimab plus pembrolizumab Phase Ib trials for mTNBC and rGBM
has its own HuPhage library and innovative selection system. PharmAbcine's
advanced 3G expression system accommodates high levels of antibody production
with high reproducibility. With its highly advanced technology platforms, it
provides high-quality antibody generation services. The high standards have
allowed PharmAbcine to expand co-development opportunities with not only
existing but also potential partners.
information about PharmAbcine, visit http://www.pharmabcine.com.